GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » 3-Year RORE %

Hyloris Pharmaceuticals (XBRU:HYL) 3-Year RORE % : 8.09% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Hyloris Pharmaceuticals's 3-Year RORE % for the quarter that ended in Dec. 2023 was 8.09%.

The industry rank for Hyloris Pharmaceuticals's 3-Year RORE % or its related term are showing as below:

XBRU:HYL's 3-Year RORE % is ranked better than
70.69% of 1399 companies
in the Biotechnology industry
Industry Median: -7.59 vs XBRU:HYL: 8.09

Hyloris Pharmaceuticals 3-Year RORE % Historical Data

The historical data trend for Hyloris Pharmaceuticals's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals 3-Year RORE % Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year RORE %
Get a 7-Day Free Trial - - 22.02 4.64 8.09

Hyloris Pharmaceuticals Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.02 -7.56 4.64 0.42 8.09

Competitive Comparison of Hyloris Pharmaceuticals's 3-Year RORE %

For the Biotechnology subindustry, Hyloris Pharmaceuticals's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyloris Pharmaceuticals's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's 3-Year RORE % falls into.



Hyloris Pharmaceuticals 3-Year RORE % Calculation

Hyloris Pharmaceuticals's 3-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.563--0.45 )/( -1.397-0 )
=-0.113/-1.397
=8.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 3-year before.


Hyloris Pharmaceuticals  (XBRU:HYL) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Hyloris Pharmaceuticals 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyloris Pharmaceuticals (XBRU:HYL) Business Description

Traded in Other Exchanges
Address
Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.

Hyloris Pharmaceuticals (XBRU:HYL) Headlines